Posted by Michael Wonder on 13 Aug 2019
Windtree announces FDA fast track designation for istaroxime
13 August 2019 - Fast track designation highlights the potential for istaroxime to address unmet medical needs of patients hospitalised with acute heart failure.
Windtree Therapeutics today announced that the U.S. FDA has granted fast track designation for istaroxime for the treatment of acute heart failure.
Istaroxime is a first-in-class, dual action, luso-inotropic agent in clinical development for the treatment of acute heart failure with reduced ejection fraction.
